Baird lowered the firm’s price target on Science 37 to $1.00 from $2.00 and keeps an Outperform rating on the shares. The analyst said the company remains highly speculative and a very different story versus. de-SPAC, but we believe the platform has more value than the negative EV ascribed by the Market.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on SNCE:
- Science 37 Reports Fourth Quarter and Full Year 2022 Financial Results
- Science 37 sees FY23 revenue $55M-$60M, consensus $73.66M
- Science 37 reports Q4 EPS (57c), consensus (18c)
- Science 37 to Present at the Cowen 43rd Annual Health Care Conference
- Science 37 to Report Fourth Quarter 2022 Financial Results on March 6, 2023